Your shopping cart is currently empty

Flonoltinib (JAK2/FLT3-IN-1) is an orally active and potent JAK2/FLT3 inhibitor, inhibiting JAK2, FLT3, JAK1, and JAK3. Flonoltinib has anti-cancer activity and can be used for studying myeloproliferative neoplasms.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $68 | In Stock | In Stock | |
| 5 mg | $121 | In Stock | In Stock | |
| 10 mg | $194 | In Stock | In Stock | |
| 25 mg | $311 | In Stock | In Stock | |
| 50 mg | $511 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $133 | In Stock | In Stock |
| Description | Flonoltinib (JAK2/FLT3-IN-1) is an orally active and potent JAK2/FLT3 inhibitor, inhibiting JAK2, FLT3, JAK1, and JAK3. Flonoltinib has anti-cancer activity and can be used for studying myeloproliferative neoplasms. |
| Targets&IC50 | JAK3:39 nM, JAK1:26 nM, JAK2:0.7 nM, FLT3:4 nM |
| In vitro | Flonoltinib (0.005-0.1 μM; for 2 hours) has a dose-dependent effect on the induction of apoptosis in the MV4-11 cells. Flonoltinib (0.008-1 μM; for 2 hours) down-regulates p-FLT3 in a dose-dependent manner from 0.008 to 1 μM. Flonoltinib (0.005-0.1 μM; for 2 hours) strongly induces cell cycle arrest with a G1/G0 percentage of 85% at 100 nM in the MV4-11 cells. |
| In vivo | Flonoltinib exhibits significant antitumor effects and the tumor growth inhibitory rates (TGI) were respective 58% and 93% in the MV4-11-bearing mice model. |
| Synonyms | JAK2/FLT3-IN-1 |
| Molecular Weight | 467.58 |
| Formula | C25H34FN7O |
| Cas No. | 2387765-27-5 |
| Smiles | FC1=CC(=CC=C1N2CCC(N(C)CCO)CC2)NC=3N=CC(=C(N3)C=4C=NN(C4)C(C)C)C |
| Relative Density. | 1.26 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 20 mg/mL (42.77 mM), Sonication is recommended. | |||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Saline: 2 mg/mL (4.28 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.